LIFESTANCE HLTH.GRP -,01 Aktie

Lifestance Health’s stock rose to a 52-week high of 11.77 USD (current price 11.78 USD), giving it a market capitalization of 4.35 billion USD. InvestingPro rates the stock as slightly overvalued despite a 148% price gain over the past year. Operationally, LifeStance reported strong Q2 results: adjusted EPS of 0.06 USD (expected 0.03 USD), revenue of 435.35 million USD (+26% year-on-year) and adjusted EBITDA of 66 million USD (+94%), after which the full-year guidance was raised. » More on de.investing.com

LifeStance Health's stock rose to a new 52-week high of $11.63 after gaining 174.41% over the past year. Market capitalization stands at $4.48 billion, and revenue for the last twelve months grew by 16.5%. Analysts consider the stock close to its fair value and expect net income growth; Goldman Sachs rates the stock as "Neutral" with a $9.00 price target. In addition, existing shareholders completed a secondary placement of 35 million shares at $8.15, while the company repurchased 6 million of those shares at the price paid by the underwriter. » More on de.investing.com

Lifestance Health shares rose to a 52-week high of $8.90 after a year-to-date gain of 79.72% and a market capitalization of about $3.44 billion. InvestingPro rates the stock as undervalued based on fair-value calculations. Selling shareholders completed a public offering of 35 million shares; Lifestance received no proceeds but repurchased 6 million shares at $8.15. Goldman Sachs initiated coverage with a "Neutral" rating and a $9.00 price target; J.P. Morgan was involved as an underwriter. » More on de.investing.com